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Objective: Regulation of anabolic and catabolic factors is considered essential in maintaining the
homoeostasis of healthy articular cartilage. In this study we investigated the inﬂuence of RNA binding
proteins (RNABPs) in this process.
Design: Using small interfering RNA (siRNA), RNABP expression was knocked down in SW1353 chon-
drosarcoma cells and human articular chondrocytes. Gene expression and messenger RNA (mRNA) decay
of anabolic (SOX9, Aggrecan) and catabolic (matrix metalloproteinase (MMP)13) factors were analysed
using reverse transcription quantitative polymerase chain reaction (RT-qPCR). RNA-electromobility shift
assays (EMSAs) were used to investigate RNABP interactions with the SOX9 mRNA 30 untranslated region
(UTR). Immunohistochemical localisation of MMP13 and the RNABP human antigen R (HuR) was per-
formed in E13.5 and E16.5 mouse embryo sections.
Results: SOX9 mRNA, mRNA half-life and protein expression were increased with siRNA targeting the
RNABP tristetraprolin (TTP) in both HACs and SW1353s. TTP knockdown also stimulated aggrecan mRNA
expression but did not affect its stability. RNA-EMSAs demonstrated that adenine uracil (AU)-rich ele-
ments in the SOX9 mRNA 30UTR interacted with chondrocyte proteins with three speciﬁc elements
interacting with TTP. HuR knockdown signiﬁcantly increased MMP13 expression and also regulated the
expression of a number of known transcriptional repressors of MMP13. HuR was ubiquitously expressed
within mouse embryos yet displayed regional down-regulation within developing skeletal structures.
Conclusion: This study demonstrates for the ﬁrst time how RNABPs are able to affect the balance of
anabolic and catabolic gene expression in human chondrocytes. The post-transcriptional mechanisms
controlled by RNABPs present novel avenues of regulation and potential points of intervention for
controlling the expression of SOX9 and MMP13 in chondrocytes.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Articular chondrocytes are responsible for the maintenance of
the highly specialised extracellular matrix (ECM) of articular carti-
lage, found within diarthrodial joints and their phenotype is char-
acterised by the expression of cartilage ECM components such as
collagen type II and aggrecan1. Both of these genes are regulated by
SOX9, a transcription factor, which is an essential component of
transactivation complexes that encode for cartilage ECM compo-
nents (for review see Ref. 2). Healthy cartilage tissue persistso: S.R. Tew, Department of
ronic Disease, University of
4 7TE, UK. Tel: 44-(0)-151-
r Ltd on behalf of Osteoarthritis Rethrough the controlled breakdown and synthesis of ECM factors by
chondrocytes. This breakdown ismediated by specialised proteases,
such as those from thematrixmetalloproteinase (MMP) family. One
member of this family, the collagenase MMP13, has been particu-
larly implicated in the breakdown of the cartilage collagen type II
network3, and therefore articular surface destruction4.
The ability to regulate anabolic and catabolic factors in the joints
has the scope to be of considerable importance in treating disorders
of cartilaginous tissues. It is known that SOX9 is down regulated in
osteoarthritic articular cartilage and ageing intervertebral disc5,6.
Forced expression of SOX9 in chondrocytes7 or in cells from the
nucleus pulposus8 promotes the formation of cartilaginous ECM
demonstrating that driving SOX9 expression forms an important
component of strategies to regenerate cartilaginous tissues.
Conversely, inhibition of MMP13 can prevent cartilage degradationsearch Society International. This is an open access article under the CC BY license
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previously in patients with non-selective MMP inhibitors9.
A number of studies have identiﬁedmechanisms of howanabolic
and catabolic processes are regulated at the transcriptional level. For
instance, genetic studies of SOX9 in humans andmice have revealed
that the transcriptional regulation of SOX9 is very complex,
involving both long range and proximal regulatory elements10e14.
The proximal promoter of MMP13 has also beenwell characterised,
identifying binding of both transactivators and transcriptional re-
pressors15,16. In addition to transcriptional control, post-
translational control of both anabolic and catabolic factors in carti-
lage is important for controlling their function. For instance, the
SOX9 protein can be phosphorylated or sumoylated, resulting in
altered transactivation ability and proteasomal degradation
respectively17,18. In addition, it has been well established that MMP
activity can be controlled through conversion of the enzymes from
inactive pro-forms and by interactions with inhibitors such as the
tissue inhibitors of metalloproteinases (TIMPs)19,20.
A further potential tier of regulation is post-transcriptional
regulation of messenger RNAs (mRNAs), a complex process
controlled interactions of microRNAs (miRNAs) and RNA binding
proteins (RNABPs) with target mRNAs. These interactions can alter
mRNA half-life and are often closely linked to translation control as
well21. miRNA and RNABP binding often occur at sites within the 30
untranslated region (UTR) of the target mRNAs. These regions
contain seeding sites for miRNAs and many also contain adenine
uracil (AU)-rich elements (AREs), which often harbour binding sites
for RNABPs such as tristetraprolin (TTP), human antigen R (HuR),
KH RNA binding protein (KSRP) and AU-rich element ribonucleic
acid (RNA) binding protein 1 (AUF-1)22.
We have been interested in the control of chondrocyte genes
post-transcriptionally and have demonstrated that a number of
mRNAs exhibit altered decay rates in osteoarthritic chondrocytes
compared to those from healthy tissue. Furthermore we have
separately shown that SOX9 expression can be controlled post-
transcriptionally in response to cellular stress and that its mRNA
half-life negatively correlates with overall SOX9 mRNA levels in
chondrogenic constructs derived from both human articular
chondrocyte (HAC) and human bone marrow derived stem
cells23e25. A role is emerging for miRNAs in the post-transcriptional
control of chondrocyte genes such as SOX926,27 but a clear role for
RNABP regulation of gene expression in these cells is not yet
established. Interestingly however, HuR knockout during murine
embryonic development leads to a severe skeletal dysplasia28. This
study therefore aimed to determine the role that RNABPs may play
in the regulation of anabolic and catabolic mRNA levels in chon-
drocytes in vitro.Materials and methods
Cell culture
Osteoarthritic human articular cartilage was obtained following
total knee arthroplasty with full approval from the Cheshire
Research Ethics Committee. Primary articular chondrocytes were
isolated from tissue, dissected from intact, non-ﬁbrillated areas of
the articular surface by overnight digestion in growth media
(Dulbecco's Modiﬁed Eagles Medium (DMEM) containing 10%
Foetal Bovine Serum (FBS), 100 units/ml penicillin, 100 units/ml
streptomycin, 5 mg/ml amphotericin B) supplemented with 0.08%
collagenase type II (all from Invitrogen, Paisley, UK). Cells were
plated at high density (1  105 cells/cm2) and cultured in growth
media before being used at the end of ﬁrst or second passage.
SW1353 chondrosarcoma cells were maintained in the samegrowth media before their use in the experiments. All cell culture
was carried out at 37C in a 5% CO2 environment.
Small interfering RNA (siRNA) mediated gene knockdown
SW1353 cells or HACs were grown to 90e95% conﬂuence and
transfected with 10 pmol/cm2 control siRNA (product sc-37007,
Santa Cruz Biotechnology, Santa Cruz, CA) or siRNA targeting TTP
(Life Technologies, Warrington, UK), KSRP, HuR or AUF-1 (Santa
Cruz Biotechnology, Santa Cruz, CA) to cause RNABP knockdown.
For multiple knockdown of RNABP, overall siRNA exposure in all
conditions was normalised to that of a triple knockdown by
appropriate addition of control siRNA to a ﬁnal overall siRNA con-
centration of 30 pmol/cm2. All transfections were carried out using
Lipofectamine 2000 (Invitrogen, Paisley, UK) following manufac-
turer's instructions with the cells cultured in growth mediumwith
penicillin, streptomycin and amphotericin B omitted. Cultures were
analysed 24e48-h after transfection.
Real time polymerase chain reaction (PCR)
Total RNA was isolated from cell cultures using Tri Reagent
(Sigma, Poole, UK) and reverse transcribed using Molony-murine
leukemia virus (M-MLV) reverse transcriptase, primed using
random primers (Promega, Madison, WI). Real time PCR was per-
formed on an ABI 7300 system using GoTaq® qPCR Master Mix
(Promega). Expression levels were calculated by the 2DCt method29
with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the
reference expression gene using primers described in Table I.
Western blotting
Chondrocyte cell lysates were extracted using 1 reducing so-
dium dodecyl sulfate (SDS) sample buffer, separated on 4e12%
NuPAGE gels (Invitrogen) and blotted onto nitrocellulose. Blots
were probed with antibodies recognising SOX9 (AB5535 from
Merck-Millipore, Watford, UK), TTP (Sak21 a further gift from Dr
Andrew Clark), HuR (antibody 19F12, Santa Cruz Biotechnology,
Santa Cruz, CA), KSRP (antibody Ab33291, Abcam, Cambridge, UK),
AUF-1 (a kind gift from Dr Gary Brewer, University of Medicine and
Dentistry of New Jersey, USA) and GAPDH (Sigma, Poole, UK) using
previously described protocols24. Blots were visualised using a UVP
ChemiDoc-It Imaging System.
RNA decay analysis
mRNA decay rate was determined in SW1353 cells 48 h after
siRNA transfection. Real time PCR was used to quantify expression
levels in complementary DNA (cDNA) generated from cells cultured
with 1 mM actinomycin D (Sigma) for different times24.
Generation of biotinylated RNA probes
Anti-sense deoxyribonucleic acid (DNA) templates, compli-
mentary to the probe sequences in Table II, were purchased from
Eurogentec. Templates encoding mutated versions of probes 5 and
6 were also obtained where the AUUUA region of the ﬁnal RNA
would be changed to AGGGA. The 30 end of each DNA template
included the following anti-sense T7 sequence e CCCTA-
TAGTGAGTCGTATTA. A sense T7 oligo (TAATACGACTCACTATAGGG)
was annealed to each of the SOX9 30UTR templates at equimolar
concentrations in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM
Ethylenediaminetetraacetic acid (EDTA)) by heating at 95C for
5 min and allowing the probes to cool slowly to room temperature
before storing at 4C. A T7 High Yield RNA Synthesis Kit (New
Table I
Sequences of primers used for qRT-PCR analysis
Target gene Forward primer 50e30 Reverse primer 50e30
GAPDH ATGGGGAAGGTGAAGGTCG TAAAAGCAGCCCTGGTGACC
SOX9 TCCAAGCGCATTACCCACTT GTTGATTTCGCTGCTCCATTTAG
TTP TCAGCGCTCCCACTCTCG GGCTCTCGTAGATGGCAGTCAG
HuR TTCACCACCAGGCGCAGAGA GAGCCCGCTCATGTGATCGA
KSRP CCAAGGACTTCAATGACAGAAG CCTGTTGGATTTTGTTAATTTGTTCA
Aggrecan TCGAGGACAGCGAGGCC TCGAGGGTGTAGCGTGTAGAGA
AUF-1 GGTGGTTTTGGTGAGGTGGAATC CCCACGCCTCTTATTGGTCTTGT
COL2A1 GGCAATAGCAGGTTCACGTACA CGATAACAGTCTTGCCCCACTT
MMP13 TCCCAGGAATTGGTGATAAAGTAGA CTGGCATGACGCGAACAATA
RUNX2 GGAGTGGACGAGGCAAGAGTTT AGCTTCTGTCTGTGCCTTCTGG
USF1 CCCAGGGCTCAGAGGCACTG GCGTTTCTCATCCCGAGTCGTC
SP1 GGGGCCCAATGGACAGGTCAG TGAGGCAATGGGTGTGAGAGTGGT
GATA1 TGGAGACTTTGAAGACAGAGCGGCTGAG GAAGCTTGGGAGAGGAATAGGCTGCTGA
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transcription of the RNA probes according to the manufacturer's
instructions. RNA was then puriﬁed using phenol chloroform and
ethanol precipitation. To create probes for electromobility shift
assay (EMSA), the RNAs were 30 biotinylated with T4 RNA ligase
using a RNA 30 End Biotinylation Kit (Thermo Scientiﬁc, MA, USA)
according to the manufacturer's instructions.RNA-EMSAs
Conﬂuent HAC monolayer cultures were washed twice with
phosphate buffered saline (PBS) and lysates prepared in EMSA
extraction buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethane
sulfonic acid (HEPES), 150 mM KCl, 4 mM MgCl2, 0.5 mM dithio-
threitol (DTT), 0.5% Nonidet P-40 (Sigma) and complete protease
inhibitor cocktail tablet (Roche, Basel, Switzerland)) using a cell
scraper. The lysates were incubated with 40 ng of the biotinylated
RNA probes in binding buffer (10 mM Tris HCl pH 7.5, 50 mM KCl,
1 mMDTT), 5% glycerol and 500 mg/ml transfer RNA (tRNA) in a ﬁnal
volume of 20 ml. The reaction mixture was incubated at 4C for
20min before the addition of 5 ml 5 loading buffer (50mMTris HCl
pH 6.8, 0.01% bromophenol blue, 25% glycerol). Samples were then
resolved by electrophoresis on a 0.5% TriseborateeEDTA non-
denaturing 6% polyacrylamide gel (Life Technologies, CA, USA) at
200 V for 1 h on ice. Probes and proteins in the gel were then
transferred to Biodyne B nylon membranes (0.45 mM, Thermo Sci-
entiﬁc) at 400mA for30minon ice. Ultraviolet (UV) crosslinkingwas
then performed on the membranes at 0.120 J/cm2. Biotinylated RNA
probes were detected using a chemiluminescent nucleic acid
detection kit (Thermo Scientiﬁc) according to the manufacturer's
instructions and signal detection was achieved by exposing the
membranes to a charge-coupled device (CCD) camera.
For recombinant TTP EMSAs, biotinylated RNA probes were
either incubated with recombinant GST-TTP (Abnova) or with
glutathione S-transferase (GST) alone as control. For probeTable II
EMSA RNA probe sequences
Probe
number
RNA probe sequence*
1 AUUUUGUUUUUUCUUCUUCUUCUUCUUCCUUAAAGACAUUUAAGCUAAAGG
2 GUAUGUACUGUGUAUGAUUCAUUACCAUUUUGAGGGGAUUUAUACAUAUUU
3 UCUUACAAAAAGAAAAAAAAAAUCCUGUUGUAUUAACAUUUAAAAACAGAAU
4 UUGGGGGUUAACUUUGCUUAAUUCCUCAGGCUUUGCGAUUUAAGGAGGAGC
5 AGCAGUUAACCUUCAAGACAUUCCACUUGCUAAAAUUAUUUAUUUUGUAAGG
6 GUUAAAUUAUGUUCUUAACUGUAACCAGUUUUUUUUUAUUUAUCUCUUUAA
7 GAUUGCUUUUUAAAAAAGACAGCAAACUUUUUUUUUUAUUUAAAAAAAGAU
8 UUUUAAAAAGAUACUUCUGUAACUUAAGAAACCUGGCAUUUAAAUCAUAUUU
* AUUUA pentamer sequences in each probe are underlined.
y Reference sequence used Entrez accession number NM_000346.competitor EMSAs, HAC protein lysates were incubated for
20min at 4Cwith non-biotinylated RNA probes before the addition
of the corresponding biotinylated RNA probes. Non-biotinylated
competitor RNA probes were added at 0-, 1- and 10-fold excess.
Immunohistochemistry
E13.5 or E16.5 CBAF1 mouse embryos were ﬁxed in cold 4%
paraformaldehyde for 30 min, processed into parafﬁn wax blocks
and cut into 10 mm sections. The sections were stained with either
anti HuR or anti MMP13 antibodies (N16 goat polyclonal and H230
rabbit polyclonal respectively from Santa Cruz Biotechnology, CA,
USA) and localisation visualised using appropriate horseradish
peroxidase-conjugated secondary antibodies with 3,30-dia-
minobenzidine as a substrate. Sections were then dehydrated,
cleared in xylene and permanently mounted. The sections were
examined and photographed using a Nikon Eclipse 80i microscope.
Statistical analysis
In siRNA experiments using SW1353 and HAC cells, expression
levels were normalised to control conditions and datawas analysed
using either one-way analysis of variance (ANOVA) or repeated
measures ANOVA followed byDunnett's post hoc test, or one-sample
t testing. Paired data sets were analysed using paired t test. All data
wasnormally distributed as determinedbystudyingQeQplots. Data
analysis was performed using SPSS software (IBM Corporation).
Results
Altered TTP expression regulates SOX9 mRNA levels in human
chondrocytes
To investigate whether RNABPs could be involved in chon-
drocyte mRNA regulation we knocked down their expression usingBase location in SOX9 mRNA
relative to stop codon
(base location in full length mRNA)y
CAACUCGUACCCAAAUUUCCAAGACACA 117e195 (2018e2095)
UUAGAUAAAAUUAAAUGCUCUUAUUUUU 451e529 (2352e2429)
UGUGUUAUGUGAUCAGUUUUGGGGGUU 611e689 (2511e2589)
UGCCUUAAAAAAAAAUAAAGGCCUUAUU 681e759 (2581e2659)
AGAGGUUUUAAUUAAAACAAAAAAAAA 1088e1166 (2988e3066)
UCUUUUUUUAUUAUUAAAAGCAAGUUUC 1248e1326 (3149e3226)
AUAUUAACAGUUUUAGAAGUCAGUAGAA 1675e1753 (3576e3653)
UGUCUUUAGGUAAAAGCUUUGGUUUGU 1812e1890 (3712e3790)
B.T. McDermott et al. / Osteoarthritis and Cartilage 24 (2016) 1263e12731266a siRNA approach and examined expression of the mRNA and
protein of the chondrocyte transcriptional regulator SOX9. In
SW1353 chondrosarcoma cells, siRNA treatment resulted in
knockdown of the targeted proteins to around 25% of control levels
[Fig. 1(A)]. When SOX9 mRNA levels were examined in siRNA-
treated SW1353 cells, we observed an increase in expression in
cultures with reduced TTP expression [Fig. 1(B)]. We further
examined SOX9 protein levels in these cultures and found that,
consistent with the mRNA ﬁndings, SOX9 protein levels were
increased when TTP expression was knocked down [Fig. 1(C)]. We
extended our siRNA studies to examine HACs cultured as second
passage monolayers and found in these cells that TTP knockdownCo
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Fig. 1. Knockdown of TTP leads to increased expression of SOX9 in human chondrocytic cel
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and KSRP was found to be less effective when TTP siRNA was co-
transfected with either HuR or KSRP siRNA, suggesting TTP also
regulates the expression of KSRP and HuR or inﬂuences the RNA
interferance (RNAi) mechanism. TTP knockdown alone was shown
to be as effective as multiple RNABP knockdowns in signiﬁcantly
increasing SOX9 mRNA expression in both SW1353 [Fig. 2(A)] and
HACs [Fig. 2(B)].RNABP knockdown results in the regulation of both anabolic and
catabolic chondrocyte mRNAs
In addition to the anabolic transcriptional regulator SOX9, we
also examined the mRNA expression of the anabolic ECM compo-
nent aggrecan and the catabolic collagenase MMP13 in chon-
drocytes where RNABP had been knocked down (Fig. 2). We found
that aggrecan, like SOX9, was upregulated in cultures where TTP
had been knocked down. Knockdown of multiple RNABPs did not
attenuate the effect of TTP knockdown alone on aggrecan mRNA
expression. MMP13 expressionwas not affected by TTP knockdown
alone, but was instead signiﬁcantly upregulated in cultures where
HuR had been knocked down. However, induction of MMP13 was
signiﬁcantly and reproducibly attenuated, in cultures where TTP
was knocked down alongside HuR (i.e., HuR þ TTP orC T K H TK TH KH TK
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knockdown of HuR under these conditions. Responses to RNABP
knockdown were comparable between SW1353 and HAC experi-
ments on the whole although inconsistencies were evident.
Notably these were in the responses of aggrecan where levels were
elevated by all conditions except KSRP knockdown alone in
SW1353 but only by knockdown of TTP alone, TTP þ KSRP and
TTP þ HuR in HAC. A further inconsistency was the response of
SOX9 to KSRP þ HuR knockdown conditions where signiﬁcant up-
regulation was observed in SW1353 cells but not in HACs.TTP knockdown creates a more stable pool of SOX9 transcripts
To determine whether TTP affects the post-transcriptional
regulation of the anabolic mRNAs SOX9 and aggrecan, we per-
formed actinomycin D chase experiments to determine the rate of
decay of each mRNA in SW1353 cells following knockdown of the
different RNABPs (Fig. 3). We found that SOX9 mRNA was turned
over quickly, as we have previously observed23,24. Interestingly, the
rate of SOX9 mRNA decay appeared to be attenuated by TTP
knockdown. By performing linear regression analysis of log2
transformed data on each replicate separately we found that SOX9
mRNA mean half-life under control conditions was 2.6 h (±1.3 95%
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Fig. 3. TTP knockdown stabilises SOX9 mRNA. SW1353 were transfected with Control
(black unﬁlled circles), TTP (black unﬁlled triangles), KSRP (grey ﬁlled triangles) and
HuR siRNA (grey unﬁlled squares) for 48 h and then subjected to a 5-h actinomycin D
chase. RNA was harvested for real time PCR analysis for mRNA decay of SOX9 and
aggrecan as indicated. Data is normalised to 0 h actinomycin D treatment (grey dashed
line) and individual data points from three independent experiments are presented.
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resulted in a stabilisation of the SOX9 mRNA, increasing its half-life
to 6.2 h (±4.3 95% conﬁdence interval, n ¼ 3, P ¼ 0.004 e ANOVA
with Dunnett's post hoc test). Aggrecan mRNAwas found to be very
stable in the SW1353 cells (half-life > 10 h) and it was not
detectably affected by knockdown of any of the RNABPs.Chondrocyte proteins interact with the SOX9 30UTR
We were interested in studying how the 30UTR of SOX9 can
interact with proteins in chondrocytes. We have previously studied
the sequence of this region of SOX9 mRNA and found that it con-
tains AREs, speciﬁcally eight AUUUA pentamers23. We synthesised
probes of approximately 100 bases in length spanning each motif
(Table II) using in vitro transcription and then 30 end labelled the
probes with biotin. Three of the AREs (present in probes 5, 6 and 7)
contain the sequence UAUUUAU and represent strong candidate
TTP binding sites based on previous deﬁnitions30. To examine the
role of TTP interactions with SOX9 30UTR AREs, we performed
EMSA analysis with probes incubated with recombinant TTP. We
found that TTP interacted with probes 5, 6 and 7 only [Fig. 4(A)].
When the AUUUA pentamer was mutated in probe 5 and 6 to
AGGGA, this interaction was lost [Fig. 4(B)]. Further EMSA analysis
revealed that proteins within chondrocyte lysates interacted withﬁve of the eight probes; probes 1, 3, 5, 6 and 7, and that this
interaction could be inhibited in a dose-dependent manner with
unlabelled competitor probes [Fig. 4(C)]. A sixth probe, probe 2,
exhibited a faint and less convincing interaction with chondrocyte
lysates. Using mutated probes 5 and 6 we found that whilst most of
the cell lysate interactions were not dependent upon the AUUUA
sequence, some highmolecular weight complexeswere diminished
when using mutant probe 6 [Fig. 4(D)].
HuR knockdown does not affect the decay rate of MMP13 but
increases the expression of known transcriptional repressors
We examined the effect of RNABP knockdown on the mRNA
decay of MMP13 in SW1353 and found that, like aggrecan, its
transcript was very stable and that an affect of RNABP knockdown
on turnover was not observed, despite overall mRNA levels being
increased when HuR was knocked down [Fig. 5(B)]. Note that
knockdown of HuR did not affect its own RNA stability [Fig. 5(A)].
Because MMP13 mRNA levels were increased when HuR was
knocked down, we examined whether HuR had any effect on
known transcriptional repressors of MMP13. We measured mRNA
decay of four repressors in SW1353 cells [Fig. 5(B)]. We found an
overall decrease in mRNA expression of RUNX2 and SP1 but no
change in their mRNA decay rate in cells treated with HuR siRNA. A
decrease in USF1 expression was also seen in the HuR knockdown
cultures, which did seem to be associatedwith a stabilisation of this
mRNA. GATA1 was not affected by HuR knockdown.
HuR protein is spatially regulated in developing chondrocytes
The regulation of MMP13 by HuR is particularly interesting
given that MMP13 is expressed in terminally differentiating chon-
drocytes during endochondral ossiﬁcation and that HuR knockout
in mouse embryos causes a strong skeletal phenotype28. We
decided to follow up on our observations by examining the protein
localisation of HuR, and MMP13, in developing mouse cartilage at
both E13.5 and E16.5 using immunohistochemistry. As has been
well established, we found that, in general, HuR is expressed
ubiquitously throughout the developing embryo. However we did
note speciﬁc reductions in its abundance associated with cartilag-
inous structures. Firstly, we found that the condensing mesen-
chyme in the digits at E13.5 exhibited a “checkerboard” distribution
of cells whichwere strongly HuR positive alongside cells withmuch
weaker staining [Fig. 6(A and B)]. Furthermore, analysis of the more
mature costal cartilage at E13.5, revealed that, compared to nearby
lung tissue which mostly contained cells that highly express HuR,
the rib cartilage can be separated into high expressing resting and
proliferative cells and then much lower expressing hypertrophic
cells [Fig. 6(B and D)]. We found similar evidence of reduced
expression of HuR in hypertrophic chondrocytes in costal cartilage
in E16.5 embryos (data not shown) and also in the long bones of the
fore and hind limb [Fig. 6(E)]. Interestingly, we noted that HuR
levels were low or absent in cells adjacent to the perichondrium in
E16.5 long bones [Fig. 6(F)]. Using serial sections of E16.5 embryos
we then examined the relationship between HuR and MMP13
protein expression. In the long bones we again observed that HuR
expressionwas reduced in hypertrophic chondrocytes [Fig. 6(G and
I)].We found that MMP13was located in the hypertrophic zone and
that in earlier stages of differentiation was often in chondrocytes
that had undetectable or reduced levels of HuR present [Fig. 6(H
and I)]. The MMP13 in these reduced HuR cells was predominantly
cell associated. This inverse pattern of HuR and MMP13 staining
was restricted to these hypertrophic chondrocytes as MMP13 was
also strongly expressed in mineralising bone where cellular HuR
was also abundant [Fig. 6(H)].
Fig. 4. TTP interacts with SOX9 ARE-containing 30UTR sequences. (A) EMSAwas performed using the SOX9 30UTR probes incubated with either GST or GST-TTP. Arrowhead indicates
free probe and * indicates TTP-dependent gel shift. (B) EMSA with the SOX9 30UTR probes 5 and 6 containing mutant AREs (P5M and P6M) incubated with either GST or GST-TTP.
Arrowhead indicates free probe and * indicates TTP-dependent gel shift. (C) EMSA of six SOX9 30UTR probes (numbers 1, 3, 5, 6 and 7) which demonstrated interactions with HAC
protein lysates. Probes were incubated with 0-, 1- and 10-fold excess of non-biotinylated competitor probes prior to incubation with the lysate. Arrowhead indicates free probe and *
indicates cell lysate induced gel shift. (D) EMSA of control (P5, P6) or mutant probes (P5M, P6M) incubated with (þ) or without () HAC cell lysate. Arrowhead indicates free probe
and * indicates cell lysate induced gel shift.
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In this study we begin to examine how RNABPs that are known
to modulate post-transcriptional gene expression, affect anabolic
and catabolic gene expression in chondrocytes and have identiﬁed
potentially opposing effects of TTP and HuR.
TTP is a zinc ﬁnger-containing protein, which has an established
role in the post-transcriptional control of a number of inﬂamma-
tory cytokines31e33. We have demonstrated through our knock-
down studies that TTP acts as a suppressor of SOX9 expression
levels. We have also shown that reduced TTP levels lead to stabi-
lisation of the SOX9 mRNA and that it can bind to AREs within the
SOX9 mRNA 30UTR. This data points to a role for TTP as a modulator
of SOX9 mRNA decay. However, the modest scale of the effect that
we observe, taken together with our existing understanding of
post-transcriptional control of SOX9 indicate that it is likely to
contribute to the relative instability of the SOX9 transcript as part of
a larger regulatory mechanism. Mice deﬁcient in TTP develop
normally but quickly develop a tumor necrosis factor alpha (TNFa)-
dependent autoimmune syndrome, which includes the develop-
ment of inﬂammatory arthritis as they age34,35. The lack of a severe
skeletal phenotype in the TTP / mice would argue against TTP
mediated post-transcriptional regulation having a signiﬁcant effect
on cartilage development; however, it is likely that this form ofregulation is subtler and may assist in controlling SOX9 mRNA
levels and responsiveness during the maintenance of cartilage
homoeostasis. Furthermore, there may be a degree of redundancy
in the post-transcriptional process with other factors contributing
alongside TTP in regulating SOX9 mRNA. SOX9 forms part of
transactivation complexes to regulate gene expression and is
known to interact with SOX5 and SOX6 as part of this process.
Analysis of the 30UTR of these genes' human mRNAs indicates that
SOX6 in particular has the potential for post-transcriptional regu-
lation that may parallel that of SOX9 (analysis of Genbank accession
NM_01145811, data not shown). It contains six UAUUUAU motifs,
similar to those that we have shown TTP interacts with in the SOX9
mRNA. Therefore, it would be interesting to develop this work
further to clarify how SOX6 is post-transcriptionally controlled into
SOX9 in chondrocytes.
In addition to protein binding, interactions of mRNA 30UTR el-
ements with miRNAs also perform a critical role in post-
transcriptional gene control at the level of both mRNA decay and
translation regulation. A previous study has indicated that miR-124
can regulate SOX9mRNA through interactions with sequences in its
30UTR36. This regulation helped to drive the differentiation of
progenitor cells inhabiting the subventricular zone stem cell niche.
More recent studies have shown that miR-145 is a negative regu-
lator of SOX9 expression in chondrocytes26,27. Furthermore, miR-
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Fig. 5. MMP13 mRNA stability and its transcriptional repressors are unaffected by HuR knockdown. SW1353 cells were transfected with either control or HuR siRNA and then
subjected to a 6-h actinomycin D chase, prior to analysing mRNA stability using real time PCR. mRNA decay curves for (A) HuR and (B) MMP13 are presented in addition to those of
the transcriptional regulators RUNX2 (C), GATA1 (D), Sp1 (E) and USF1 (F). Expression levels were normalised to GAPDH mRNA levels and are presented as individual data points on
the charts (n ¼ 3).
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noma37. The seed sites for each of these miRNAs lie within the SOX9
30UTR, in the region more proximal to the stop codon than the TTP
binding sites. Therefore, it is likely that the major driver of SOX9
mRNA instability is interactions of small RNAs and RNABPs within
this region. Our data indicates that TTP contributes to SOX9 mRNA
instability, but that it binds to an area of the 30UTR further down-
stream of the stop codon and may thus be outside of the main
destabilising region. It is possible that it acts a responsive element
allowingmodulation of SOX9mRNA decay rates. This would ﬁt well
with previous studies demonstrating altered activity of TTP inresponse to mitogen-activated protein kinase (MAPK) signalling38,
which is particularly interesting given our previous observations of
p38 MAPK meditated regulation of SOX9 by hyperosmolarity24.
We chose to examine the expression of catabolic genes in our
RNABP knockdown cultures. MMP13 is a collagenase, which is
considered to perform a key role in the non-reversible destruction
of the type II collagen network in cartilage during osteoarthritis39.
HuR appears to act as an overall negative regulator of MMP13, as its
knockdown leads to elevated MMP13 expression levels. However,
MMP13 mRNA is a very stable transcript and HuR levels do not
noticeably affect its rate of decay, indicating that this regulation
Fig. 6. Immunohistochemical analysis of HuR and MMP13 distribution in embryonic murine cartilage. All antibody localisation was visualised using 3,3-diaminobenzidine (brown)
and sections were counterstained with Haematoxylin (blue). (A) HuR localisation in the developing digits of the mouse forelimb at E13.5. A more highly magniﬁed view of the
central digit is shown in (B). (C) HuR localisation in the ribs and lung at E13.5. (D) HuR localisation in costal cartilage from E13.5 embryo. (E) HuR localisation in femur of E16.5
embryo. (F) Magniﬁed view of E16.5 femur showing reduced staining at the margins of the cartilage rudiment (arrowheads). (G) HuR localisation in the radius of an E16.5 embryo.
(H) Serial section of that shown in panel G, stained using MMP13 antiserum. (I & J) Magniﬁed views of the hypertrophic chondrocyte regions shown in panels G and H respectively.
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transcriptional repressors of MMP13 provides evidence for a
mechanism that could lead to this regulation, as it suppresses the
expression of candidates such as RUNX2, SP1 and USF1. It is still not
clear whether this is caused by direct modulation of the stability of
these mRNAs however, as no affect on RUNX2 and SP1 mRNA sta-
bility was noted, whilst in the case of USF1 the affect of lower levels
of HuR is to create a less abundant but more stable pool of mRNA. It
is likely that HuR's inﬂuence over multiple transcripts leads, indi-
rectly to conditions where MMP13 is up or down regulated. HuR
was of particular interest to us given that mouse knockout studies
have identiﬁed a role for it in skeletal development28. By examining
the distribution of HuR inmouse embryos we have built upon these
ﬁndings, identifying regional differences in the expression of HuR.
It is particularly interesting that despite being a widely expressed
protein, we have observed reduced levels in hypertrophic chon-
drocytes as well as in chondrocytes adjacent to the perichondrium.
These regions have been implicated in regulation of long bone
growth and mineralisation40. Furthermore, HuR in condensing
mesenchyme of the future digits at E13.5 demonstrates a “check-
erboard” appearance of HuR staining, which could be relevant to
the on-going differentiation of this tissue. Further work is now
required to identify how the altered levels of HuR we observe
contribute to skeletal development.
In conclusion, we have shown that the TTP and HuR can
contribute in opposing ways to control the balance of anabolic and
catabolic gene expression in human chondrocytes. It is still not
clear what the context is for this level of regulation in chondrocyte
biology and to what degree these proteins act alongside otherfactors to control this process. However, post-transcriptional con-
trol mechanisms represent a fascinating means of modulation of
important chondrocyte regulatory genes, which might provide
important targets for the treatment of joint diseases such as
osteoarthritis.
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